For General Information, page-1106

Correct
They have 13% of ambulant boys( yet to show efficacy)
SRP- 9001 adds another 6% of ambulant boys ( I think)
Here’s the thing
Atl1102 will work with all DMD drugs.. Ambulant and Non Ambulant

Ask yourself
Why did the FDA allow a drug to market? That showed no efficacy (eg Sarepta x2 drugs)
Smart move by the FDA
Sarepta had a MC of $12 billion at one stage.
Sarepta was able to raise $ millions( mega)
Using that money to do more and more research..
They haven’t got a drug to show efficacy as yet..
but with all that $$ money they can employ more and more Scientists…
So the FDA in their wisdom made the right call.

Where does that leave Anp?
Working on a shoestring budget.. with no $$ to further our pipeline.. Sad , So very sad!

But we do have options and it’s not to late!

We have to have people presence in the US to sell our story…eg JL from IHL.. setting up for a successful trial.

This is why Anp has to move now and not tomorrow
We need young people with a Scientific / Financial background and a “go get” attitude ( not just depend on Edison to promote Anp)
We need those people to get fresh investors/ Funds/ Venture Capital etc to join our register or make us offers $$
Lets not sit here .. waiting for 16 months waiting for results from the DMD trial..




$5 in time